BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22382581)

  • 21. Effective removal of methotrexate by high-flux hemodialysis.
    Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
    Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
    Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
    Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature.
    Kibby D; Trinkman H
    Pediatr Blood Cancer; 2024 Mar; 71(3):e30831. PubMed ID: 38149827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Drug Monitoring of Methotrexate in Plasma Using Ultra High-Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry: Necessary After Administration of Glucarpidase in Methotrexate Intoxications.
    Mulder MB; Huisman R; Engels FK; van der Sluis IM; Koch BCP
    Ther Drug Monit; 2018 Aug; 40(4):383-385. PubMed ID: 29994985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commentary.
    Milone MC
    Clin Chem; 2010 Dec; 56(12):1795-6. PubMed ID: 21119036
    [No Abstract]   [Full Text] [Related]  

  • 26. Late administration of glucarpidase in methotrexate intoxication: Do we have more time than we thought?
    Miceli G; Daidone M; Corpora F; Gaudio FD; Tuttolomondo A;
    Eur J Intern Med; 2024 Jan; 119():144-145. PubMed ID: 37806838
    [No Abstract]   [Full Text] [Related]  

  • 27. Commentary.
    Fox E; Balis FM
    Clin Chem; 2010 Dec; 56(12):1795. PubMed ID: 21119037
    [No Abstract]   [Full Text] [Related]  

  • 28. "Rescue" agent may circumvent rare but deadly complication from chemotherapy.
    Jenks S
    J Natl Cancer Inst; 1997 Jun; 89(12):840-1. PubMed ID: 9196247
    [No Abstract]   [Full Text] [Related]  

  • 29. What is the best therapy for toxicity in the setting of methotrexate-associated acute kidney injury: high-flux hemodialysis or carboxypeptidase G2?
    Kumar N; Shirali AC
    Semin Dial; 2014; 27(3):226-8. PubMed ID: 24620824
    [No Abstract]   [Full Text] [Related]  

  • 30. Renal dysfunction during and after high-dose methotrexate.
    Green MR; Chamberlain MC
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
    Al-Turkmani MR; Law T; Narla A; Kellogg MD
    Clin Chem; 2010 Dec; 56(12):1792-4. PubMed ID: 21119035
    [No Abstract]   [Full Text] [Related]  

  • 32. Fixed-Dose Glucarpidase for Toxic Methotrexate Levels and Acute Kidney Injury in Adult Lymphoma Patients: Case Series.
    Truong H; Leung N
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e497-e502. PubMed ID: 33563580
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Treatment of accidental intrathecal methotrexate overdose.
    Gosselin S; Isbister GK
    J Natl Cancer Inst; 2005 Apr; 97(8):609-10; author reply 610-1. PubMed ID: 15840887
    [No Abstract]   [Full Text] [Related]  

  • 34. Early intervention is important when administering glucarpidase for methotrexate intoxication.
    Bettini LR; Rizzari C
    Eur J Intern Med; 2024 Feb; 120():118-119. PubMed ID: 38102037
    [No Abstract]   [Full Text] [Related]  

  • 35. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
    Widemann BC
    Pediatr Blood Cancer; 2016 Feb; 63(2):366. PubMed ID: 26488622
    [No Abstract]   [Full Text] [Related]  

  • 36. High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
    Meyers PA; Flombaum C
    J Clin Oncol; 2011 Mar; 29(7):e180; author reply e181. PubMed ID: 21220601
    [No Abstract]   [Full Text] [Related]  

  • 37. Using a lower dose of glucarpidase to reduce plasma levels of methotrexate.
    Widemann BC
    Clin Adv Hematol Oncol; 2013 May; 11(5):324-5. PubMed ID: 23880720
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful use of intrathecal carboxypeptidase G2 for intrathecal methotrexate overdose: a case study and review of the literature.
    Bradley AM; Buie LW; Kuykendal A; Voorhees PM
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):166-70. PubMed ID: 23084403
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetics and Pharmacodynamics of Glucarpidase Rescue Treatment After High-dose Methotrexate Therapy Based on Modeling and Simulation.
    Kimura T; Fukaya Y; Hamada Y; Yoshimura K; Kawamoto H
    Anticancer Res; 2023 May; 43(5):1919-1924. PubMed ID: 37097666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
    Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.